GlassScriptPhysician profile
Payal Soni
NPI 1871936898
$1,350.11
in general payments reported to CMS, 2019-2025
38 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $88.13 · 2023: $246 · 2024: $535 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,261.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $165.70 | 2023-2024 | Optune |
| Janssen Biotech, INC. | $113.17 | 2023-2025 | Rybrevant, Carvykti, Darzalex |
| Bayer Healthcare Pharmaceuticals INC. | $92.78 | 2023-2025 | |
| Palette Life Sciences, INC. | $65.47 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.48 | 2024 | Fruzaqla, Ninlaro |
| Eisai INC. | $49.24 | 2023-2024 | |
| Siemens Medical Solutions USA, INC. | $41.76 | 2022-2023 | Acuson Sequoia Diagnostic Ultrasound System |
| Novartis Pharmaceuticals Corporation | $38.61 | 2023-2025 | |
| Adaptive Biotechnologies Corporation | $37.12 | 2024-2025 | Clonoseq |
| Incyte Corporation | $35.74 | 2024-2025 | Zynyz, Jakafi |
| Emd Serono, INC. | $35.38 | 2025 | |
| Genmab U.S., INC. | $34.67 | 2023-2024 | Tivdak, Epkinly |
| Abbvie INC. | $33.73 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $33.41 | 2024-2025 | Orgovyx |
| Kyowa Kirin, INC. | $33.26 | 2024-2025 | Poteligeo |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $33.25 | 2024-2025 | Zoladex |
| Stemline Therapeutics INC. | $31.59 | 2023-2025 | Orserdu |
| Dendreon Pharmaceuticals LLC | $31.43 | 2024-2025 | Provenge |
| Daiichi Sankyo INC. | $29.58 | 2023-2025 | Enhertu, Injectafer |
| Acrotech Biopharma INC. | $28.28 | 2024 | Beleodaq |
| Adc Therapeutics America, INC. | $28.15 | 2025 | |
| Genzyme Corporation | $21.66 | 2025 | |
| Lilly USA, LLC | $20.87 | 2024 | Verzenio, Jaypirca |
| Iovance Biotherapeutics, INC. | $20.44 | 2025 | Amtagvi |
| Glaxosmithkline, LLC. | $19.78 | 2025 | Jemperli, Zejula |
| Boston Scientific Corporation | $19.23 | 2025 | Spaceoar System |
| Azurity Pharmaceuticals, INC. | $19.07 | 2025 | Danziten, Vivimusta |
| Invivyd INC | $18.69 | 2025 | Pemgarda |
| Astrazeneca Pharmaceuticals LP | $18.68 | 2024 | Imfinzi |
| Janssen Pharmaceuticals, INC | $18.40 | 2024 | Xarelto |
| Teleflex LLC | $17.46 | 2025 | Barrigel |
| Apellis Pharmaceuticals, INC. | $16.98 | 2024 | Empaveli |
| Aveo Pharmaceuticals, INC. | $16.94 | 2024 | |
| Sobi, INC | $15.89 | 2025 | |
| Pfizer INC. | $15.80 | 2024 | |
| Kite Pharma, INC. | $15.08 | 2025 | Yescarta |
| Pharmaessentia USA Corporation | $14.46 | 2025 | Besremi |
| Spectrum Pharmaceuticals INC. | $13.88 | 2023 | Rolvedon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Payal Soni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.